Goerttler K, Löhrke H, Hesse B
Institute of Experimental Pathology, German Cancer Research Center, Heidelberg, GFR.
Carcinogenesis. 1980 Aug;1(8):707-13. doi: 10.1093/carcin/1.8.707.
In this study a new modification of the systemic 2-stage carcinogenesis experiment is described. Tumors were induced in NMRI-mice using a single intravaginal application of the carcinogen 7,12-dimethylbenz[a]anthracene (DMBA) (initiator) followed by intravaginal treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) (promotor) as a cocarcinogen over a period of 52 weeks. The substances were applied using small tampons. Development of preneoplastic lesions or neoplasias was not found in the group of untreated control animals (n = 50) and in TPA treated animals (n = 50). However, mice which had been treated with TPA alone showed pronounced hyperplasia. When DMBA was applied without subsequent treatment with TPA (n = 100), formation of preneoplastic lesions was frequently observed. Fibroepitheliomas (papillomas), carcinomas and sarcomas, typically located intravaginally and at the external region of the vagina, were observed after the combined treatment with DMBA and TPA (n = 100). In addition, benign as well as malignant tumors were found, mainly in the forestomach, in DMBA treated animals and more frequently after application of DMBA and TPA. Tumors of the lung and leukemias were identified more frequently in comparison to the normal spontaneous tumor rate in NMRI mice, and were probably in part caused by the promoting substance TPA. On the other hand, no significant tumor formation in the mammary gland and in the ovaries was observed after DMBA/TPA application. The tumors observed in these organs were, however, caused by treatment with the carcinogen DMBA only. This new modification of the 2-stage experiment, i.e. the direct intravaginal application of initiating and promoting substances, has special relevance for the elucidation of the mechanisms involved in the development of carcinomas located at the portio vaginalis uteri in humans.
本研究描述了一种系统性两阶段致癌实验的新改良方法。使用致癌物7,12-二甲基苯并[a]蒽(DMBA)(启动剂)经阴道单次给药诱导NMRI小鼠发生肿瘤,随后在52周内用12-O-十四酰佛波醇-13-乙酸酯(TPA)(促癌剂)经阴道治疗作为共致癌物。这些物质通过小棉球给药。在未处理的对照动物组(n = 50)和TPA处理的动物组(n = 50)中未发现癌前病变或肿瘤形成。然而,仅用TPA处理的小鼠出现了明显的增生。当单独应用DMBA而不随后用TPA处理时(n = 100),经常观察到癌前病变的形成。在DMBA和TPA联合处理后(n = 100),观察到纤维上皮瘤(乳头状瘤)、癌和肉瘤,典型地位于阴道内和阴道外部区域。此外,在DMBA处理的动物中发现了良性和恶性肿瘤,主要位于前胃,在应用DMBA和TPA后更频繁。与NMRI小鼠的正常自发肿瘤发生率相比,肺肿瘤和白血病的发生率更高,可能部分是由促癌物质TPA引起的。另一方面,在应用DMBA/TPA后,未观察到乳腺和卵巢中有明显的肿瘤形成。然而,这些器官中观察到的肿瘤仅由致癌物DMBA处理引起。这种两阶段实验的新改良方法,即直接经阴道应用启动剂和促癌剂,对于阐明人类子宫阴道部癌发生机制具有特殊意义。